Baseline characteristics of the primary Sjögren's syndrome study population (n=28)
| Variable | Mean±SD or n (%) | Median (range) |
|---|---|---|
| Age (years) | 43±14 | 40 (18–70) |
| Female gender, n (%) | 27 (96) | |
| Disease duration (months) | 80±48 | 64 (14–183) |
| IgG (g/l) | 22.5±7.4 | 21.3 (12.8–41.5) |
| IgM-Rf (kIU/l) | 143±164 | 90 (7–783) |
| Anti-Ro/SSA positive, n (%) | 28 (100) | |
| Anti-La/SSB positive, n (%) | 20 (71) | |
| SWS (ml/min) | 0.42±0.37 | 0.31 (0.02–1.47) |
| Rituximab course number, n (%) | ||
| 1st | 8 (29) | |
| 2nd | 15 (54) | |
| 3rd | 3 (11) | |
| 4th | 2 (7) | |
| ESSPRI | 6.3±2.2 | 6.7 (0.3–9.0) |
| ESSDAI | 8±5 | 8 (2–18) |
| Constitutional domain, n (%)* | 12 (43) | |
| Lymphadenopathy domain, n (%)* | 0 (0) | |
| Glandular domain, n (%)* | 17 (61) | |
| Articular domain, n (%)* | 8 (29) | |
| Cutaneous domain, n (%)* | 4 (14) | |
| Pulmonary domain, n (%)* | 3 (11) | |
| Renal domain, n (%)* | 1 (4) | |
| Muscular domain, n (%)* | 0 (0) | |
| PNS domain, n (%)* | 2 (7) | |
| CNS domain, n (%)* | 0 (0) | |
| Haematological domain, n (%)* | 11 (39) | |
| Biological domain, n (%)* | 24 (86) | |
| Patient's GDA | 58±22 | 60 (15–93) |
| Physician's GDA | 53±16 | 55 (20–80) |
Values are presented as mean±SD unless otherwise indicated.
↵* Number (%) of patients having any degree of activity per ESSDAI domain (score of at least 1).
CNS, central nervous system; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity; IgM-Rf, rheumatoid factor; PNS, peripheral nervous system; SWS, stimulated whole salivary flow.